ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today announced that it has with immediate effect appointed Bryan, Garnier & Co. Limited as its joint corporate broker to act alongside Northland Capital Partners who remain the Company’s Nominated Adviser and joint corporate broker.
Tim McCarthy, Chairman of ImmuPharma, commented: “We welcome Bryan Garnier as Joint Broker. Bryan Garnier provides ImmuPharma with deep healthcare expertise and pan European broking capability, to support the Company as we progress towards commercialisation.”
Olivier Garnier, Founder and Managing Partner of Bryan, Garnier & Co. commented: “We are delighted to be appointed and we look forward to working with the Company at this very exciting time.”
ImmuPharma is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange, focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma is led by a commercially focused Board and management team with extensive experience.
